# US 2012/0252738 A1 · Tubulin Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252738 A1
- Document ID: US20120252738A1
- Status: Published application
- Kind: A1
- Application number: 13/509,055
- Filed: 2010-11-12
- Published: 2012-10-04
- Earliest claimed: 2009-11-12
- Assignees: R&D-Biopharmaceuticals GmbH
- Inventors: Wolfgang Richter
- Web page: https://patentgrep.com/patent/US20120252738A1

## CPC

- C07K 5/06139: {with the first amino acid being heterocyclic}
- A61K 38/07: Tetrapeptides
- A61P 35/00: Antineoplastic agents
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07K 5/00: Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K 5/02: containing at least one abnormal peptide link
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases.

## Claims

### Claim 1

Compound of formula (I):
wherein
R is H, an alkyl, alkenyl, alkynyl, CO-alkyl, heteroalkyl, aralkyl or heteroaralkyl group, all of which may optionally be substituted;
R′ is OH, an alkyl, alkenyl, alkynyl, —O—CO-alkyl or heteroalkyl group, all of which may optionally be substituted;
R″ is a group of formula CO2H, CO2R′″, CONHR′″, CONR2′″, with R′″ independently being an alkyl, aryl, aralkyl or heteroalkyl group;
X is S or O;
Y is independently optionally substituted alkyl, optionally substituted heteroalkyl, halogen, CN, NO2 or OH;
n is 0, 1, 2, 3, 4 or 5;
or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof.

### Claim 2 (depends on 1)

Compound according to claim 1 wherein R is C1-C6 alkyl.

### Claim 3 (depends on 1)

Compound according to claim 1, wherein R′ is —O—CO-alkyl, alkyl or heteroalkyl.

### Claim 4 (depends on 1)

Compound according to claim 1, wherein R″ is CO2H.

### Claim 5 (depends on 1)

Compound according to claim 1, wherein R″ is a group of formula CO2R′″, CONHR′″ or CONR2′″, with R′″ being an alkyl, aryl, aralkyl or heteroalkyl group.

### Claim 6 (depends on 1)

Compound according to claim 1, wherein X is S.

### Claim 7 (depends on 1)

Compound according to claim 1, wherein Y is independently optionally substituted alkyl, halogen or OH and n is 1.

### Claim 8 (depends on 1)

Compound according to claim 1, wherein n is 0.

### Claim 9 (depends on 1)

Compound according to claim 1 wherein R is propyl, R′ is O-Acetyl, X is S, n is O and R″ is CO2H.

### Claim 10 (depends on 1)

Pharmaceutical composition containing a compound according to claim 1 and optionally one or more carriers or adjuvants.

### Claim at position 11

11-12. (canceled)

### Claim 13 (depends on 1)

A method for preventing or treating cancer comprising administering a compound of claim 1 to a subject in need thereof, thereby preventing or treating the subject's cancer.

### Claim 14 (depends on 10)

A method for preventing or treating cancer comprising administering a pharmaceutical composition of claim 10 to a subject in need thereof, thereby preventing or treating the subject's cancer.
